Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Alzheimer’s Disease: Advances in Drug Development

Abstract : As of 2018, Alzheimer's disease (AD) is the most common form of neurodegenerative dementia. It contributes to a progressive neuron loss, deterioration of memory, and cognitive impairment. Current therapies may provide a symptomatic benefit, but do not treat the underlying process. Ongoing researches focus on understanding the causal mechanisms and finding neuropathological hallmarks of AD. Therapeutic approaches targeting senile plaques or neurofibrillary tangles have not yet resulted in a significant cognitive improvement. However, recent data according to the analysis of AD clinical trials ( database) show promising results. This literature review aims at summarizing the recent advances and at highlighting the most promising results of the ongoing researches. It compares the merits of small-molecules, antibodies, cell, and gene-based therapies and emphasizes the need for treatment at earlier stages of the disease.
Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : Laurianne Adin <>
Soumis le : mardi 18 septembre 2018 - 10:31:56
Dernière modification le : vendredi 15 mai 2020 - 12:22:09




Morgane Piton, Christophe Hirtz, Caroline Desmetz, Jacqueline Milhau, Anne Dominique Lajoix, et al.. Alzheimer’s Disease: Advances in Drug Development. Journal of Alzheimer's Disease, IOS Press, 2018, 65 (1), pp.3 - 13. ⟨10.3233/JAD-180145⟩. ⟨hal-01876065⟩



Consultations de la notice